117 related articles for article (PubMed ID: 18955814)
21. [Proteasome and proteolysis].
Papapostolou D; Reboud-Ravaux M
J Soc Biol; 2004; 198(3):263-78. PubMed ID: 15662944
[TBL] [Abstract][Full Text] [Related]
22. Inhibitors for the immuno- and constitutive proteasome: current and future trends in drug development.
Huber EM; Groll M
Angew Chem Int Ed Engl; 2012 Aug; 51(35):8708-20. PubMed ID: 22711561
[TBL] [Abstract][Full Text] [Related]
23. Physalin B, a novel inhibitor of the ubiquitin-proteasome pathway, triggers NOXA-associated apoptosis.
Vandenberghe I; Créancier L; Vispé S; Annereau JP; Barret JM; Pouny I; Samson A; Aussagues Y; Massiot G; Ausseil F; Bailly C; Kruczynski A
Biochem Pharmacol; 2008 Aug; 76(4):453-62. PubMed ID: 18577376
[TBL] [Abstract][Full Text] [Related]
24. Proteasome inhibitors: Dozens of molecules and still counting.
de Bettignies G; Coux O
Biochimie; 2010 Nov; 92(11):1530-45. PubMed ID: 20615448
[TBL] [Abstract][Full Text] [Related]
25. Development and characterization of proteasome inhibitors.
Bo Kim K; Fonseca FN; Crews CM
Methods Enzymol; 2005; 399():585-609. PubMed ID: 16338383
[TBL] [Abstract][Full Text] [Related]
26. Indolo-phakellins as β5-specific noncovalent proteasome inhibitors.
Beck P; Lansdell TA; Hewlett NM; Tepe JJ; Groll M
Angew Chem Int Ed Engl; 2015 Feb; 54(9):2830-3. PubMed ID: 25581903
[TBL] [Abstract][Full Text] [Related]
27. New polyhydroxy sterols: proteasome inhibitors from a marine sponge Acanthodendrilla sp.
Tsukamoto S; Tatsuno M; van Soest RW; Yokosawa H; Ohta T
J Nat Prod; 2003 Sep; 66(9):1181-5. PubMed ID: 14510593
[TBL] [Abstract][Full Text] [Related]
28. The human immunodeficiency virus (HIV)-1 protease inhibitor saquinavir inhibits proteasome function and causes apoptosis and radiosensitization in non-HIV-associated human cancer cells.
Pajonk F; Himmelsbach J; Riess K; Sommer A; McBride WH
Cancer Res; 2002 Sep; 62(18):5230-5. PubMed ID: 12234989
[TBL] [Abstract][Full Text] [Related]
29. Exploiting nature's rich source of proteasome inhibitors as starting points in drug development.
Gräwert MA; Groll M
Chem Commun (Camb); 2012 Feb; 48(10):1364-78. PubMed ID: 22039589
[TBL] [Abstract][Full Text] [Related]
30. HIV protease-mediated activation of sterically capped proteasome inhibitors and substrates.
Buckley DL; Corson TW; Aberle N; Crews CM
J Am Chem Soc; 2011 Feb; 133(4):698-700. PubMed ID: 21186803
[TBL] [Abstract][Full Text] [Related]
31. The therapeutic potential of the proteasome in leukaemia.
McCloskey SM; McMullin MF; Walker B; Irvine AE
Hematol Oncol; 2008 Jun; 26(2):73-81. PubMed ID: 18324639
[TBL] [Abstract][Full Text] [Related]
32. Retro hydrazino-azapeptoids as peptidomimetics of proteasome inhibitors.
Aubin S; Martin B; Delcros JG; Arlot-Bonnemains Y; Baudy-Floc'h M
J Med Chem; 2005 Jan; 48(1):330-4. PubMed ID: 15634028
[TBL] [Abstract][Full Text] [Related]
33. Targeting the ubiquitin-proteasome pathway with inorganic compounds to fight cancer: a challenge for the future.
Dalla Via L; Nardon C; Fregona D
Future Med Chem; 2012 Mar; 4(4):525-43. PubMed ID: 22416778
[TBL] [Abstract][Full Text] [Related]
34. Proteasome inhibition up-regulates p53 and apoptosis-inducing factor in chondrocytes causing severe growth retardation in mice.
Zaman F; Menendez-Benito V; Eriksson E; Chagin AS; Takigawa M; Fadeel B; Dantuma NP; Chrysis D; Sävendahl L
Cancer Res; 2007 Oct; 67(20):10078-86. PubMed ID: 17942942
[TBL] [Abstract][Full Text] [Related]
35. New pigments from the terrestrial cyanobacterium Scytonema sp. collected on the Mitaraka inselberg, French Guyana.
Bultel-Poncé V; Felix-Theodose F; Sarthou C; Ponge JF; Bodo B
J Nat Prod; 2004 Apr; 67(4):678-81. PubMed ID: 15104503
[TBL] [Abstract][Full Text] [Related]
36. The ubiquitin proteasome system and efficacy of proteasome inhibitors in diseases.
Chitra S; Nalini G; Rajasekhar G
Int J Rheum Dis; 2012 Jun; 15(3):249-60. PubMed ID: 22709487
[TBL] [Abstract][Full Text] [Related]
37. Synthesis and proteasome inhibition of lithocholic acid derivatives.
Dang Z; Lin A; Ho P; Soroka D; Lee KH; Huang L; Chen CH
Bioorg Med Chem Lett; 2011 Apr; 21(7):1926-8. PubMed ID: 21388808
[TBL] [Abstract][Full Text] [Related]
38. Targeting the ubiquitin+proteasome system in solid tumors.
Driscoll JJ; Woodle ES
Semin Hematol; 2012 Jul; 49(3):277-83. PubMed ID: 22726552
[TBL] [Abstract][Full Text] [Related]
39. Targeting the ubiquitin proteasome system in haematological malignancies.
Crawford LJ; Irvine AE
Blood Rev; 2013 Nov; 27(6):297-304. PubMed ID: 24183816
[TBL] [Abstract][Full Text] [Related]
40. Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation.
Kwan JC; Eksioglu EA; Liu C; Paul VJ; Luesch H
J Med Chem; 2009 Sep; 52(18):5732-47. PubMed ID: 19715320
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
